Your browser doesn't support javascript.
loading
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.
Hollebecque, Antoine; Salvagni, Stefania; Plummer, Ruth; Niccoli, Patricia; Capdevila, Jaume; Curigliano, Giuseppe; Moreno, Victor; de Braud, Filippo; de Villambrosia, Sonia Gonzalez; Martin-Romano, Patricia; Baudin, Eric; Arias, Marina; de Alvaro, Juan; Parra-Palau, Josep L; Sánchez-Pérez, Tania; Aronchik, Ida; Filvaroff, Ellen H; Lamba, Manisha; Nikolova, Zariana; de Bono, Johann S.
Afiliación
  • Hollebecque A; Gustave Roussy, Département d'innovation thérapeutique et essais précoces, Villejuif, France.
  • Salvagni S; S. Orsola Polyclinic, Malpighi University Hospital, Bologna, Italy.
  • Plummer R; Clinical and Translational Research Institute Northern, Newcastle University, Newcastle, UK.
  • Niccoli P; Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France.
  • Capdevila J; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, IOB-Teknon, Barcelona, Spain.
  • Curigliano G; European Institute of Oncology, IRCCS, University of Milan, Milan, Italy.
  • Moreno V; START Center for Cancer Care, Jimenez Diaz University Hospital, Madrid, Spain.
  • de Braud F; National Cancer Institute, Milan, Italy.
  • de Villambrosia SG; Department of Hematology, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.
  • Martin-Romano P; Gustave Roussy, Département d'innovation thérapeutique et essais précoces, Villejuif, France.
  • Baudin E; Gustave Roussy, Département d'innovation thérapeutique et essais précoces, Villejuif, France.
  • Arias M; Gustave Roussy, Département D'oncologie Endocrinienne, Villejuif, France.
  • de Alvaro J; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
  • Parra-Palau JL; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
  • Sánchez-Pérez T; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
  • Aronchik I; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
  • Filvaroff EH; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Lamba M; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Nikolova Z; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • de Bono JS; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
Cancer ; 128(17): 3185-3195, 2022 09 01.
Article en En | MEDLINE | ID: mdl-35737639
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B de la Zona Marginal / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B de la Zona Marginal / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Francia